BioLife Solutions (BLFS), Bellicum Pharmaceuticals (BLCM) Enter CryoStor Supply Agreement

August 10, 2016 6:08 AM EDT

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

BioLife Solutions, Inc. (NASDAQ: BLFS) announced that it has entered into a ten year supply agreement with Bellicum Pharmaceuticals, a leading developer of cellular immunotherapies for cancers and orphan inherited blood disorders.

BioLife's CryoStor clinical grade cell freeze media is incorporated into Bellicum's manufacturing process for several cellular immunotherapies targeting blood cancers and solid tumors.

Mike Rice, BioLife President & CEO, commented, "We are pleased to support Bellicum with this long term supply agreement, which underscores the value and utility of our biopreservation media products in the high growth cell therapy industry. The last half of 2016 and 2017 will be very exciting and encouraging for cancer patients, our customers, and BioLife shareholders. Several customers' cellular immunotherapies continue to progress through late stage clinical trials and the BLA submission and regulatory approval process. As these customers obtain regulatory approvals and commence commercial scale manufacturing, we expect significantly increased demand for CryoStor and HypoThermosol®, our best in class biopreservation media products."

BioLife management estimates that CryoStor and HypoThermosol, BioLife's cell and tissue storage and shipping media, are incorporated into more than 220 pre-clinical validation projects and clinical trials of cell-based therapies targeting blood cancers, solid tumors, vision loss, heart disease, stroke, and movement disorders such as osteoarthritis.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Management Comments

Related Entities

Twitter, Earnings

Add Your Comment